Currently Viewing:
Formulary Decisions in HCV
Currently Reading
Segment 10: Hepatitis C Costs in the Spotlight
February 12, 2015
Segment 12: A New Precedent for Healthcare
February 12, 2015
Segment 13: Making HCV Care Sustainable for All Patients
February 12, 2015

Segment 10: Hepatitis C Costs in the Spotlight

In the last year the hepatitis C drug market has gained a lot of attention in the healthcare industry despite the fact that oncology as a specialty drug market has been very expensive for years now.
In the last year the hepatitis C drug market has gained a lot of attention in the healthcare industry despite the fact that oncology as a specialty drug market has been very expensive for years now.

Matthew D. Harman, PharmD, MPH, believes most of the attention is likely because these drugs were priced as orphan drugs even though hepatitis C is not an orphan condition.

“This class grew by almost $14 billion in 2014; we’ve never had a single class impact our drug spend in such a way,” Steven Miller, MD, MBA, said. “And so I think that’s clearly why this became the number one topic for many of us in healthcare last year.”

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up